However, Hatcher had the most sacks (3) and Bowen also had his moments this season; and both played a lot less than Spears did. Spears is a first round pick who has eight career sacks hasn’t lived up to the hype (Ware was drafted the same year and has 64.5 sacks). It would be cheaper to keep Hatcher and Bowen and give them more playing time while drafting someone (however, that could be hard with just six picks) than it would to keep Spears and one of the other two. If they do keep Spears they should seriously consider having him play defensive tackle along with Jay Ratliff. Junior SaiviiI don’t see a way for him to stay in Dallas, he was serviceable as Ratliff’s backup, but didn’t impress anyone. Whether it’s through the draft or the Cowboys moving Spears to DT they won’t resign him.It’s just easier to find someone else. L.P LadouceurThe Cowboys will give Ladouceur a fourth round tender or just work something out with him for a little more than the league minimum. He’s a great long snapper but does nothing else and he knows it. Still the Cowboys won’t give him up, a solid long snapper goes a long way (just ask the 2002 Giants). Duke Preston/Cory Procter/Pat McQuistan Procter played in limited action during the season, mostly special teams. Preston and McQuistan have been in the league four and five years respectively and if they haven’t made a splash yet they’re not going to. The Cowboys will keep Procter around for depth, but if they just draft a couple guys and don’t keep him no one’s going to miss any of these players. *Allen Rossum is a RFA, but the Cowboys have no interest in him at all. . CALGARY, April 30 /PRNewswire-FirstCall/ – Oncolytics Biotech Inc. (TSX: ONC,NASDAQ: ONCY) announced today that its 2009 Annual and Special Meeting of theShareholders will be held on Tuesday, May 5, 2009 at 2:30 p.m.
(MT) at theTelus World of Science, 701-11 Street SW, Calgary.Following the business portion of the meeting, Dr. Oncolytics’ clinicalprogram includes a variety of Phase I/II and Phase II human trials usingREOLYSIN, its proprietary formulation of the human reovirus, alone and incombination with radiation or chemotherapy. For further information aboutOncolytics, please visit presentation time is subject to change. This release and the presentationrelated thereto contain forward-looking statements which involve known andunknown risks, delays, uncertainties and other factors not under the Company’scontrol and which may cause actual results, performance or achievements of theCompany to be materially different from the results, performance orexpectations implied by these forward-looking statements. Such risks anduncertainties include, among others, the efficacy of REOLYSIN as a cancertreatment, the success and timely completion of clinical studies and trials,uncertainties related to the research and development of pharmaceuticals,uncertainties related to the regulatory process and general changes to theeconomic environment. Investors should consult the Company’s quarterly andannual filings with the Canadian and U.S.
securities commissions foradditional information on risks and uncertainties relating to theforward-looking statements. Investors are cautioned against placing unduereliance on forward-looking statements. The Company does not undertake toupdate these forward-looking statements except as required by applicable laws.SOURCEOncolytics Biotech Inc.Oncolytics Biotech Inc., Cathy Ward, 210, 1167 Kensington Cr NW, Calgary,Alberta, T2N 1X7, Tel: (403) 670-7377, Fax: (403) 283-0858,; The Equicom Group, Nick Hurst, 325, 300 5th Ave. SW,Calgary, Alberta, T2P 3C4, Tel: (403) 538-4845, Fax: (403) 237-6916,; The Investor Relations Group, Erika Moran, 11 StoneSt, 3rd Floor, New York, NY, 10004, Tel: (212) 825-3210, Fax: (212) 825-3229,. Tuesday, the students voted in favor of a new mascot & the favorite is Admiral Ackbar.